In fall 2024, the BIOSECURE Act, which blocked the United States (US)’s government’s use of goods and services from Chinese biotech companies, sailed through the US House of Representatives only to become stalled in the US Senate.[1] This is only one in a series of US government (USG) efforts to…
On September 9, the BIOSECURE Act, which this blog series has been covering since March, passed by a huge majority in the United States (US) House of Representatives. The essence of the act is the termination of direct and indirect US government dealings with five Chinese biotech companies (Complete Genomics,…
The most recent and prominent United States (US) attempt to limit cooperation with Chinese life science businesses has stalled, but is hardly dead. Current Speaker of the House Mike Johnson said he intends to have the BIOSECURE Act signed into law before the end of 2024.[1] Irrespective of the impasse,…
In January 2024, Congressman Mike Gallagher, the Chair of the United States (US) House Committee on the Chinese Communist Party, introduced the “Biosecure Act,” which prohibits the US government (USG) from “procuring or obtaining biotechnology equipment or services produced or provided by a biotechnology company of concern,” participating in a…
The Belt and Road Initiative (BRI) has generated so much commentary that it is conceivable that if one printed out all the relevant pages and laid them end-to-end the length might approach that of all the railway track laid under the aegis of the BRI![i] Further commentary seems even more…
China, as you would expect, Belt and Road Initiative (BRI) participants and proponents, and even data support some of the positive sentiment in, if not the logic of, the previous blog in this four-part series on the future of the BRI, which highlighted numerous factors likely to continue propelling the…
My last blog highlighted the debate raging about the health of China’s Belt and Road Initiative (BRI).[1] It also reviewed the economic and political rationales for China’s ambitious scheme. This blog takes the position that the BRI is neither dead nor on life-support. Such claims ignore the array of enduring…
The Belt and Road Initiative (BRI), which consists of two main components, the sea-focused Maritime Silk Road Initiative (MSRI) and the land-focused Silk Road Economic Belt (SREB), came into being in 2013.[1] Since Chinese President Xi Jinping launched the MSRI and the SREB, there has been considerable positive and negative…
This is the last in a four-part series that has looked inter alia at debates surrounding China’s protection of foreign intellectual property (IP) rights (IPR), detailed China’s problematic fulfillment of its IPR commitments, and examined various factors potentially driving China’s poor compliance with its IPR obligations. The focus of this…
In my last blog, I detailed China’s continuing shortcomings with protecting intellectual property (IP) rights (IPR) and the emergence of new challenges. The question arises as to why these problems persist even though it has been more than 20 years since China joined the World Trade Organization (WTO), is…
